Primary immunodeficiency diseases (PIDD) market encompasses a diverse group of more than 200 immune disorders, many of which result from single-gene defects. The defects lead to increased susceptibility to recurrent and persistent infections. Diseases if left un/misdiagnosed, leads to chronic illness, disability, reduced working capacity, decreased quality of life for patients and families, permanent organ damage and even death. All forms of PIDs are rare and have an overall prevalence of approximately 1:10,000 live births with the exception of IgA deficiency. The global primary immunodeficiency diseases market was valued at US$ 4,367.4 Mn in 2014 and is projected to reach US$ 7,562.8 Mn by 2023, expanding at a CAGR of 6.1% from 2015-2023. The report also provided pipeline analysis (qualitative) for Phase I and II drug candidates whereas a complete quantitative (US$ Mn) aspect is illustrated for Phase III drugs.
Request a Sample Copy of the Report @ http://www.mrrse.com/sample/1424
The report analyzed the PIDD market from four perspectives: by Disease, by Test, by Treatment and by Geography. In terms of market by disease, the overall market is segmented into three broad sub-categories: Antibody Deficiency, Cellular Immunodeficiency and Innate Immune Disorder. Pertaining to disease segment, the study illustrates that the antibody deficiency market accounts for the largest share in 2014 and expected to be the fastest growing segment throughout the forecast tenure i.e. from 2015-2023. Prime attributors for antibody deficiency diseases market include high incidence rate which is approximately 60% – 70% of PIDD cases and intensive research and development activities in developed countries. CVID is the most common clinically significant PID with a prevalence of around 1 in 25,000.
Tests that are conducted for isolation and confirmation of PIDD include blood test and prenatal tests, prenatal tests account for the largest share in terms of revenue due to high cost of procedures which is primarily taken by parents having PIDD child and are expecting another child in few months. In case of an affected fetus identified through prenatal testing, couples can decide whether they wish to continue with the pregnancy or not. Some couples that are at risk for autosomal recessive disorders opt for donor sperm through the process of artificial insemination. In terms of volume, blood test market outpaces the prenatal testing but owing to low cost of diagnosis the revenue generation is significantly low as compared to prenatal testing. In blood test, complete blood count alternatively known as CBC is most conducted procedure whereas, other blood-based tests recommended for PIDD diagnosis globally include lymphocyte subpopulation and proliferation tests, granulocyte function tests, and cell protein expression tests. Pertaining to aforementioned factor the growth rate of blood test segment is expected to grow at the fastest pace during the forecast period.
Inquiry on this report @ http://www.mrrse.com/enquiry/1424
The treatment modalities for PID mainly include immunoglobulin replacement, antibiotics and bone marrow transplantation. Immunoglobulin replacement and judicious use of prophylactic antibiotics can prevent the significant end organ damage and improve long-term outcome and quality of life in many patients with PIDD if diagnosed early. Immunoglobulin replacement therapy market is expected to be the major contributing segment and the fastest growing market in the next 5-8 years. Hematopoietic stem cell transplantation is used for treating many of the severe immunodeficiency. In centers specialized in treating these conditions, the survival and cure of the disease can reach up to 95%, depending on the condition of the patient at the time of treatment and the donor availability.
Geographically, the report studies the PIDD market for four major regions: North America, Europe, Asia Pacific and Rest of the World. Owing to diagnosis rate, intensive research and development activities and reimbursement provision the market is largely dominated by the North America region which include The United States and Canada market. Asia Pacific and Rest of World (Latin America, Middle East and Africa and Others) pertaining to low awareness level and less provisions in terms of diagnostic centers the market is likely to grow at a moderate rate throughout the forecast tenure.
Read Complete Report with TOC @ http://www.mrrse.com/primary-immunodeficiency-disease-market
The market study also profiled some of the leading companies operating in primary immunodeficiency diseases market across the globe. These encompasses Baxter International, Inc., Biotest AG, CSL Behring LLC, Bio Products Laboratory Ltd., Kedrion S.p.A., LFB S.A., Octapharma AG and Grifols S.A.
90 State Street,
Albany NY – 12207